Anacor reports positive preliminary results from tavaborole Phase III onychomycosis trial
Biopharmaceutical company Anacor Pharmaceuticals has reported positive preliminary results from the first of two Phase III trials of topical anti-fungal tavaborole, designed to treat onychomycosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Onychomycosis | Pharmaceuticals